# DESCRIPTION

## ACKNOWLEDGMENT OF GOVERNMENT SUPPORT

- acknowledge government support

## FIELD

- define TGF-β monomers

## BACKGROUND

- summarize TGF-β biology

## SUMMARY

- describe engineered TGF-β monomers
- outline composition and methods

## DETAILED DESCRIPTION

### I. Abbreviations

- define abbreviations

### II. Terms and Methods

- define terms and methods
- motivate aberrant TGF-β signaling
- explain administration
- define contacting
- describe fibrosis
- introduce fusion protein
- explain glycosylation
- define heterologous
- describe isolated
- introduce monomer
- explain neoplasia
- describe PEGylation
- define peptide or polypeptide
- explain sequence identity/similarity

### III. Overview of Several Embodiments

- introduce recombinant TGF-β monomers
- describe inhibition of TGF-β signaling
- specify cysteine to serine substitution
- describe deletion of amino acid residues 52-71
- specify at least one amino acid substitution
- describe human, mouse, rat or other mammalian TGF-β monomers
- specify at least one amino acid substitution for MIL affinity
- describe human TGF-β2 monomer embodiments
- describe human TGF-β1 monomer embodiments
- describe human TGF-β3 monomer embodiments
- describe PEGylated, glycosylated, or modified TGF-β monomers

### IV. Administration of Engineered TGF-β Monomers

- describe pharmaceutical compositions
- specify isolated cells comprising a vector encoding a recombinant human TGF-β monomer
- describe pharmaceutically acceptable carriers and excipients
- outline administration methods and dosage forms

## EXAMPLES

### Example 1: An Engineered TGF-β Monomer that Functions as a Dominant Negative to Block TGF-β Signaling

- describe engineered TGF-β monomer

### BACKGROUND

- introduce TGF-β1 and TGF-β3 monomers
- describe limitations of TGF-β1 and TGF-β3 monomers
- hypothesize non-covalent dimerization of TGF-β monomers
- design engineered monomer to inhibit TGF-beta signaling
- replace interfacial α-helix with flexible loop
- limit potential of monomers to non-covalently dimerize
- eliminate contact surface for TGF-β type I receptor
- summarize nomenclature and features of dimeric and monomeric TGF-β
- show complete sequences of TGF-β variants
- express and purify human MI ectodomain and TβRII ectodomain
- describe protein expression and purification methods
- express and purify avi-tagged homodimeric TGF-β3
- express and purify mini monomeric TGF-β variants
- describe solubility assays and light scattering measurements
- describe NMR spectroscopy methods
- describe SPR binding measurements
- introduce analytical ultracentrifugation
- describe sedimentation velocity experiment
- analyze sedimentation velocity data
- summarize results
- motivate design of engineered mini-monomeric TGF-β
- describe design of mmTGF-β
- express and purify mmTGF-β
- characterize mmTGF-β folding and solubility
- analyze NMR spectrum of mmTGF-β
- determine three-dimensional structure of mmTGF-β
- evaluate receptor binding properties of mmTGF-β
- summarize physical characterization of mmTGF-β
- introduce mmTGF-β2-7M
- describe physical characterization
- describe TβRII binding affinity
- describe crystal structure
- compare with TGF-β1 and TGF-β3
- describe inhibitory activity
- describe signaling activity
- describe competition experiment
- describe IC50 values
- describe SPR experiments
- describe analytical ultracentrifugation
- describe time-resolved fluorescence resonance energy transfer
- compare mmTGF-β2-7M with mTGF-β3
- summarize results

### Discussion

- motivate TGF-β inhibitors
- describe engineered TGF-β monomer
- explain signaling activity of TGF-β1 C77S and TGF-β3 C77S
- discuss elimination of heel helix
- suggest potential applications of inhibitors
- define scope of invention

